Get started
Author

Waleed Kian

Observed names: Kian W, Kian Waleed, Kian, W., Kian, Waleed, W. Kian
Observed institutions: Ben-Gurion University of the Negev, Hebrew University of Jerusalem, Assuta Medical Center, Soroka Medical Center, Shaare Zedek Medical Center, Bikur Cholim Hospital
ORCID: 0000-0003-4956-9364
Observed ORCID: 0000-0003-4956-9364
OpenAlex ID: A5063166825
UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN)
2022 · Jair Bar, Nir Peled, et al. · Journal of Thoracic Oncology · 101
PDF
Radiological artificial intelligence - predicting personalized immunotherapy outcomes in lung cancer
2023 · Laila C. Roisman, Waleed Kian, et al. · npj Precision Oncology · 42
PDF
Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program
2022 · Oliver Illini, Hannah Fabikan, et al. · Therapeutic Advances in Medical Oncology · 30
PDF
The impact of osimertinib’ line on clonal evolution in EGFRm NSCLC through NGS-based liquid biopsy and overcoming strategies for resistance
2021 · Vered Fuchs, Laila Roisman, et al. · Lung Cancer · 27
Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study
2021 · Nir Peled, Waleed Kian, et al. · Neuro-Oncology Advances · 26
PDF
Dose escalation of osimertinib for intracranial progression in EGFR mutated non-small-cell lung cancer with brain metastases
2020 · Iris M Goldstein, Laila C Roisman, et al. · Neuro-Oncology Advances · 25
PDF
Neoadjuvant Osimertinib Followed by Sequential Definitive Radiation Therapy and/or Surgery in Stage III Epidermal Growth Factor Receptor–Mutant Non-Small Cell Lung Cancer: An Open-Label, Single-Arm, Phase 2 Study
2023 · Nir Peled, Laila C. Roisman, et al. · International Journal of Radiation Oncology*Biology*Physics · 23
Nivolumab-Induced Systemic Capillary Leak Syndrome as an Ultra Rare Life-Threatening Phenomenon of Late Toxicity and Intravenous Immunoglobulin Efficacy
2021 · Ilya Polishchuk, Alexander Yakobson, et al. · Immunotherapy · 20
Genomic profiling of solid tumors harboring BRD4-NUT and response to immune checkpoint inhibitors
2021 · Jonathan W. Riess, Shaila Rahman, et al. · Translational Oncology · 19
Associated Myocarditis: A Predictive Factor for Response?
2020 · Walid Shalata, Nir Peled, et al. · Case Reports in Oncology · 17
Crizotinib in MET Exon 14-Mutated or MET-Amplified in Advanced Disease Non-Small Cell Lung Cancer: A Retrospective, Single Institution Experience
2022 · Walid Shalata, Alexander Yakobson, et al. · Oncology · 14
Vismodegib as First-Line Treatment of Mutated Sonic Hedgehog Pathway in Adult Medulloblastoma
2020 · Waleed Kian, Laila C. Roisman, et al. · JCO Precision Oncology · 13
Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis
2024 · Oliver Illini, Felix Carl Saalfeld, et al. · International Journal of Molecular Sciences · 12
PDF
Real-world efficacy and safety of mobocertinib in EGFR exon 20 insertion-mutated lung cancer
2022 · Waleed Kian, Petros Christopoulos, et al. · Frontiers in Oncology · 11
PDF
Lung cancer screening: a critical appraisal
2021 · Waleed Kian, Melanie Zemel, et al. · Current Opinion in Oncology · 11
Overcoming CEP85L-ROS1, MKRN1-BRAF and MET amplification as rare, acquired resistance mutations to Osimertinib
2023 · Waleed Kian, Bilal Krayim, et al. · Frontiers in Oncology · 10
PDF
Liquid First Is “Solid” in Naïve Non-Small Cell Lung Cancer Patients: Faster Turnaround Time With High Concordance to Solid Next-Generation Sequencing
2022 · Or Sehayek, Waleed Kian, et al. · Frontiers in Oncology · 10
PDF
Nivolumab Induced Hepatocanalicular Cholestasis and Liver Rejection in a Patient With Lung Cancer and Liver Transplant
2020 · Marius Braun, Vered Fuchs, et al. · Journal of Thoracic Oncology · 10
PDF
Next-Generation Sequencing Liquid Biopsy-Guided Osimertinib Rechallenge in EGFR-Mutated Advanced Non-Small-Cell Lung Cancer Patients
2022 · Vered Fuchs, Waleed Kian, et al. · Clinical Drug Investigation · 8
1206P UNcommon EGFR mutations: International Case series on efficacy of Osimertinib in Real-life practice in first-liNe setting (UNICORN)
2021 · J. Bar, W. Kian, et al. · Annals of Oncology · 8
Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Mutant NSCLC Across Treatment Lines: Evidence From the TRACER/HERTras Real-World Cohort
2026 · Oliver Illini, Anna-Carina Hund, et al. · Journal of Thoracic Oncology · 7
PDF
Are we facing a cure in lung cancer?—KEYNOTE-001 insights
2019 · Aharon Y. Cohen, Waleed Kian, et al. · Annals of Translational Medicine · 7
PDF
Real-World Clinical Outcomes of Neoadjuvant Platinum-Based Chemotherapy with Nivolumab in Non-Small Cell Lung Cancer
2024 · Walid Shalata, Sameh Daher, et al. · Journal of Clinical Medicine · 6
PDF
Non-Small-Cell Lung Cancer Patients Harboring ROS1 Rearrangement: Real World Testing Practices, Characteristics and Treatment Patterns (ROS1REAL Study)
2024 · Urska Janzic, Natalie Maimon Rabinovich, et al. · Current Oncology · 6
PDF
Lung cancer screening: a critical appraisal.
2022 · Waleed Kian, Melanie Zemel, et al. · PubMed · 6
Works count: 68
Citation count: 533
H-index: 12
I10-index: 18
Year
Topic
Type